PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14693739-9	2003	Raloxifene administration increased serum IGFBP-3 [mean change 245 ng/ml; P = 0.017; 95% confidence interval (CI), 76-415] and leptin (mean change 2.1 ng/ml; P = 0.005; 95% CI, 0.6-3.7).	Raloxifene Hydrochloride	0-10	insulin like growth factor binding protein 3	Homo sapiens	42-49	
16912660-1	2006	OBJECTIVE: To evaluate in a group of postmenopausal women the effects of long-term raloxifene treatment on breast density using a digitized analysis of mammograms and on insulinlike growth factor-1 (IGF-1), insulinlike growth factor binding protein-3 (IGFBP-3), and sex hormone-binding globulin (SHBG) plasma levels.	Raloxifene Hydrochloride	83-93	insulin like growth factor binding protein 3	Homo sapiens	207-250	
16912660-1	2006	OBJECTIVE: To evaluate in a group of postmenopausal women the effects of long-term raloxifene treatment on breast density using a digitized analysis of mammograms and on insulinlike growth factor-1 (IGF-1), insulinlike growth factor binding protein-3 (IGFBP-3), and sex hormone-binding globulin (SHBG) plasma levels.	Raloxifene Hydrochloride	83-93	insulin like growth factor binding protein 3	Homo sapiens	252-259	
16912660-13	2006	Moreover, raloxifene treatment significantly reduced IGF-1 and increased IGFBP-3 and SHBG plasma levels at 24 months.	Raloxifene Hydrochloride	10-20	insulin like growth factor binding protein 3	Homo sapiens	73-80	
16912660-16	2006	Such an effect could perhaps explain the reduction in the incidence of mammary carcinoma observed in the Multiple Outcomes of Raloxifene Evaluation study probably due to the direct antiestrogenic activity of raloxifene on mammalian tissue and/or its indirect activity increasing SHBG levels or modifying the IGF-1/IGFBP-3 ratio.	Raloxifene Hydrochloride	208-218	insulin like growth factor binding protein 3	Homo sapiens	314-321	
15302288-1	2004	OBJECTIVE: To assess and compare the effect of conjugated estrogen and of the selective estrogen receptor modulator raloxifene on serum levels of insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) and on the IGF-I/IGFBP-3 ratio.	Raloxifene Hydrochloride	116-126	insulin like growth factor binding protein 3	Homo sapiens	187-231	
15302288-8	2004	In contrast to CEE, which had no effect, both raloxifene doses of 60 and 150 mg/day significantly increased serum IGFBP-3 during the 2 years.	Raloxifene Hydrochloride	46-56	insulin like growth factor binding protein 3	Homo sapiens	114-121	
15302288-9	2004	Compared with placebo, the decrease in IGF-I/IGFBP-3 ratio was -32.5% (95% CI: -20.1; -44.8%) for CEE; -16.4% (95% CI: -3.6; -29.2%) for raloxifene at 150 mg/day; and -15.4% (95% CI: -1.0; -29.8%) for raloxifene at 60 mg/day.	Raloxifene Hydrochloride	137-147	insulin like growth factor binding protein 3	Homo sapiens	45-52	
15302288-9	2004	Compared with placebo, the decrease in IGF-I/IGFBP-3 ratio was -32.5% (95% CI: -20.1; -44.8%) for CEE; -16.4% (95% CI: -3.6; -29.2%) for raloxifene at 150 mg/day; and -15.4% (95% CI: -1.0; -29.8%) for raloxifene at 60 mg/day.	Raloxifene Hydrochloride	201-211	insulin like growth factor binding protein 3	Homo sapiens	45-52	
24347426-3	2014	As a higher IGF-binding protein-3 (IGFBP3) level was observed with raloxifene co-treatment, we hypothesize that an increase in IGFBP3 reduced IGF1 bioactivity causing the attenuated anabolic effect.	Raloxifene Hydrochloride	67-77	insulin like growth factor binding protein 3	Homo sapiens	12-33	
24347426-3	2014	As a higher IGF-binding protein-3 (IGFBP3) level was observed with raloxifene co-treatment, we hypothesize that an increase in IGFBP3 reduced IGF1 bioactivity causing the attenuated anabolic effect.	Raloxifene Hydrochloride	67-77	insulin like growth factor binding protein 3	Homo sapiens	35-41	
24347426-3	2014	As a higher IGF-binding protein-3 (IGFBP3) level was observed with raloxifene co-treatment, we hypothesize that an increase in IGFBP3 reduced IGF1 bioactivity causing the attenuated anabolic effect.	Raloxifene Hydrochloride	67-77	insulin like growth factor binding protein 3	Homo sapiens	127-133	
24347426-13	2014	IGFBP3 was significantly higher during raloxifene administration, whereas no differences in IGFBP3 fragmentation were observed.	Raloxifene Hydrochloride	39-49	insulin like growth factor binding protein 3	Homo sapiens	0-6	
15302288-11	2004	CONCLUSION(S): Long-term use of both CEE and raloxifene decreases serum IGF-I and the IGF-I/IGFBP-3 ratio, but, unlike CEE, raloxifene produced a significant yet small increase in IGFBP-3.	Raloxifene Hydrochloride	45-55	insulin like growth factor binding protein 3	Homo sapiens	92-99	
15302288-11	2004	CONCLUSION(S): Long-term use of both CEE and raloxifene decreases serum IGF-I and the IGF-I/IGFBP-3 ratio, but, unlike CEE, raloxifene produced a significant yet small increase in IGFBP-3.	Raloxifene Hydrochloride	45-55	insulin like growth factor binding protein 3	Homo sapiens	180-187	
14693739-12	2003	Raloxifene administration is associated with an increase in IGFBP-3 and leptin in premenopausal high risk women.	Raloxifene Hydrochloride	0-10	insulin like growth factor binding protein 3	Homo sapiens	60-67	
34384975-3	2021	We included only trials that assessed the effect of raloxifene on IGF-1 and IGFBP-3 in adults.	Raloxifene Hydrochloride	52-62	insulin like growth factor binding protein 3	Homo sapiens	76-83	
34384975-0	2021	Effects of raloxifene administration on serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 levels: A systematic review and meta-analysis of randomized controlled trials.	Raloxifene Hydrochloride	11-21	insulin like growth factor binding protein 3	Homo sapiens	89-133	
34384975-1	2021	OBJECTIVE: To ascertain the clinical magnitude of raloxifene administration on insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) levels.	Raloxifene Hydrochloride	50-60	insulin like growth factor binding protein 3	Homo sapiens	120-164	
34384975-1	2021	OBJECTIVE: To ascertain the clinical magnitude of raloxifene administration on insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) levels.	Raloxifene Hydrochloride	50-60	insulin like growth factor binding protein 3	Homo sapiens	166-173	
11747323-0	2001	Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.	Raloxifene Hydrochloride	10-20	insulin like growth factor binding protein 3	Homo sapiens	34-41	
11397884-16	2001	At 0 h, raloxifene use was associated with lower IGF-I/IGFBP-3 ratio (4.3 +/- 0.7 vs. 2.9 +/- 0.7 and 3.0 +/- 0.7 nmol/mg; P = 0.001) and insulin/glucose ratio (13.7 +/- 5.2 vs. 11.9 +/- 5.9 and 9.5 +/- 2.3 pmol/mmol; P = 0.04).	Raloxifene Hydrochloride	8-18	insulin like growth factor binding protein 3	Homo sapiens	55-62	
11397884-17	2001	Similarly, raloxifene use was associated with lower IGF-I/IGFBP-3 and insulin/glucose ratios at 24 h (P = 0.01 and 0.07).	Raloxifene Hydrochloride	11-21	insulin like growth factor binding protein 3	Homo sapiens	58-65